2月13日，复星医药（600196/02196）发布公告，控股子公司锦州奥鸿药业有限责任公司就盐酸莫托咪酯注射液的药品注册申请获国家药品监督管理局受理。
该新药为化药1类，拟定适应症为用于麻醉诱导和短时手术麻醉。该新药的研发投入截至2026年1月约为1.89亿元（未经审计）。根据最新数据，2024年用于麻醉诱导及短时手术麻醉的同类药物在中国境内的销售额约为42.38亿元。
公告中指出，该新药在进行商业化生产前，尚需通过GMP符合性检查和获得药品注册批准，因此此次药品注册申请获受理不会对公司现阶段业绩产生重大影响。
2025年前三季度，复星医药实现收入293.93亿元，归母净利润25.23亿元。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.